Literature DB >> 1624227

The toxicity of chemically deglycosylated ricin A-chain in mice.

A M Soler-Rodriguez1, J W Uhr, J Richardson, E S Vitetta.   

Abstract

Tumor-reactive antibodies coupled to ricin or its A-chain (immunotoxins) have been used in rodents and humans to treat a variety of neoplastic diseases. Side-effects of such treatment include hepatotoxicity, vascular leak syndrome, myalgia and low grade fever. At high doses, severe toxicities include liver damage, pulmonary edema, aphasia, rhabdomyolysis and kidney failure. There have been a limited number of toxicologic studies on uncoupled ricin or its A-chain and none on deglycosylated A-chain. Since the latter has been utilized in "second generation" immunotoxins, the current studies were carried out to evaluate the toxicities induced by deglycosylated ricin A-chain (dgA) in mice. The administration of dgA to normal BALB/c mice causes early (24 h) weight loss and late (10 day) accumulation of ascites. These effects could be partially altered by changing the route of injection of dgA from i.v. to i.p. Thus, i.p. administration caused weight loss but not ascites, whereas i.v. administration caused both. Weight loss was associated with reduced fluid intake by the treated mice, and was not associated with increased levels of serum TNF-alpha. SCID mice injected with the same dose of dgA as normal BALB/c mice developed ascites, but it was of lesser severity, suggesting that a functional immune system, differences in microbial flora, or strain differences may be involved in the development of ascites.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1624227     DOI: 10.1016/0192-0561(92)90041-i

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  9 in total

1.  Ricin induces the production of tumour necrosis factor-alpha and interleukin-1 beta by human peripheral-blood mononuclear cells.

Authors:  F Licastro; M C Morini; A Bolognesi; F Stirpe
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

2.  Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.

Authors:  A J Rowland; G A Pietersz; I F McKenzie
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

3.  N-glycosylation does not affect the catalytic activity of ricin a chain but stimulates cytotoxicity by promoting its transport out of the endoplasmic reticulum.

Authors:  Qing Yan; Xiao-Ping Li; Nilgun E Tumer
Journal:  Traffic       Date:  2012-09-07       Impact factor: 6.215

4.  The need for continued development of ricin countermeasures.

Authors:  Ronald B Reisler; Leonard A Smith
Journal:  Adv Prev Med       Date:  2012-03-26

5.  Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

Authors:  R Baluna; J Rizo; B E Gordon; V Ghetie; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 12.779

6.  Linked-in: design and efficacy of antibody drug conjugates in oncology.

Authors:  Jonathan Feld; Stefan K Barta; Carolina Schinke; Ira Braunschweig; Yiyu Zhou; Amit K Verma
Journal:  Oncotarget       Date:  2013-03

Review 7.  Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Authors:  Olga Shilova; Elena Shramova; Galina Proshkina; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

8.  Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.

Authors:  Christopher Bachran; Thomas Morley; Suzanne Abdelazim; Rasem J Fattah; Shihui Liu; Stephen H Leppla
Journal:  mBio       Date:  2013-04-30       Impact factor: 7.786

9.  Characterization of Ricin and R. communis Agglutinin Reference Materials.

Authors:  Sylvia Worbs; Martin Skiba; Martin Söderström; Marja-Leena Rapinoja; Reinhard Zeleny; Heiko Russmann; Heinz Schimmel; Paula Vanninen; Sten-Åke Fredriksson; Brigitte G Dorner
Journal:  Toxins (Basel)       Date:  2015-11-26       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.